AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01641523 — intervention group
Intervention type: DEVICE
Intervention: CustomBone Service
Description: customized hydroxyapatite cranial prosthesis
Study NCT01371539 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
Study NCT00446407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Screening plus Antidepressants based on practice guidelines
Study NCT02497950 — intervention group
Intervention type: DEVICE
Intervention: HeartMate 3
Description: Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
Study NCT02802592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epogen
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study NCT04499911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic dextrose 5% in water solution
Description: The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
Study NCT04548362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meat arm
Description: Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
Study NCT04548362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starchy foods arm
Description: Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
Study NCT04702113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cipherome Lighthouse Pilot
Description: Preemptive pharmacogenomic testing
Study NCT00288314 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging, Functional
Description: Structural and functional MRI
Study NCT02802592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study NCT04557657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bio Activa
Description: Cement that release fluoride
Study NCT04557657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin Cement
Description: Resin Cement Convinonal
Study NCT03205488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
Description: 2 capsules taken once daily
Study NCT01931020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
Study NCT03205488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Description: 2 capsules taken once daily
Study NCT03205488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken once daily
Study NCT04890626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]
Description: Main randomization
Study NCT04890626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib + dexamethasone
Description: Rescue randomization
Study NCT04890626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Rescue randomization
Study NCT04928937 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass, sleeve gastrectomy
Description: bariatric surgery with the goal loosing weight
Study NCT01613599 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Participants received rituximab at the discretion of their treating physicians.
Study NCT01931020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
Study NCT00699361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 160 mg I.V.
Study NCT00699361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 160 mg intravenously (IV)
Study NCT02377401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
Study NCT04762524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH vs CVVHD
Description: Patients are initiated on CRRT in either the CVVH or CVVHD modality
Study NCT04762524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CVVH vs CVVHD
Description: Patients are initiated on CRRT in either the CVVH or CVVHD modality
Study NCT01375465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIOR drug-eluting PTCA balloon
Description: Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
Study NCT02974894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus Plantarum)
Study NCT02974894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03327168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
Study NCT02966912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg of Magnesium Oxide twice daily for 24 weeks
Study NCT02966912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open label (none)
Study NCT03435289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
Description: Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min
Study NCT02274987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized tumor board recommendation
Description: A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
Study NCT02274987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
Study NCT03327168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Controlled cold exposure is performed before and during PET/CT scan.
Study NCT02540811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCELL® ACL Scaffold
Study NCT06287554 — intervention group
Intervention type: OTHER
Intervention: PRONE POSITION
Description: early placed in prone positions within 24 hours of intubation
Study NCT01207089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: AZD8329 Oral Solution 20mg/ml
Study NCT01207089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo AZD8329 Oral Solution
Study NCT02126072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
Study NCT02126072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Volunteers consume the same volume of water as the would in wine according toe the protocol.
Study NCT01781351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping the ankle
Study NCT02831790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fontan Education Videos
Description: The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036mg/Kg) given intravenously.
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036mg/Kg) given intravenously.
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: A pill given orally.
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Study NCT02335060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill given orally with no N-acetylcysteine.
Study NCT00228865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile IV insulin therapy
Description: Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
Study NCT00228865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effects of Pulsatile IV Insulin on Cognitive functions
Description: Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
Study NCT00994994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
Study NCT00994994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
Study NCT00261703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Description: Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
Study NCT00261703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Description: Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
Study NCT00261703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cisplatin + radiotherapy
Description: Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
Study NCT00199888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124-Iodine-cG250 (124I-cG250)
Study NCT01120925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: 2-3 X 109 cells in 20ML suspension IPV in 4 min
Study NCT01120925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133
Description: 5-15 X 106 cells in 20ML suspension IPV
Study NCT01120925 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Injection of 20 ml Normal saline via IPV
Study NCT03135210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open-Chain Leg Exercise
Description: Individuals in the open-chain group will progress through standard mobility progression.
Study NCT03135210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Chain Leg Exercise
Description: Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
Study NCT00708760 — intervention group
Intervention type: BEHAVIORAL
Intervention: paper based training
Description: read selected material, test skills learned in simulator lab
Study NCT00708760 — intervention group
Intervention type: BEHAVIORAL
Intervention: web based training
Description: read and view selected web based material, test skills learned in simulator lab
Study NCT01230138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01230138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: High daily dose of 750mg administered as 250mg TID
Study NCT01230138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: High daily dose of 750mg administered as 375mg BID
Study NCT01230138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: Low daily dose of 500mg FP187 administered as 250mg BID
Study NCT01230138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: Oral tablets, up to 3 times daily for 20 weeks.
Study NCT02265315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
Study NCT02265315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lee Silverman Voice Treatment
Description: Time intensive behavioral treatment for Parkinson's hypophonia
Study NCT02265315 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lee Silverman Voice Treatment
Description: Time intensive behavioral treatment for Parkinson's hypophonia
Study NCT03250572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum ferritin
Description: serum samples and ferritin ELISA test
Study NCT02102724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil that contains omega-3 fatty acids
Description: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
Study NCT02102724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelcaps that contain 1 gram of oleic sunflower oil
Study NCT04007523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Support System
Description: Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
Study NCT04007523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP Support System
Description: A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
Study NCT03274531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of hypertensive patients to the attending physician
Description: Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
Study NCT02220933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule
Study NCT02220933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100mg capsule
Study NCT02220933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03341533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ice packs plus usual post-op analgesia
Description: A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
Study NCT03341533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual post-op analgesia
Description: Standard post-operative analgesia orders will be followed.
Study NCT03341533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-op analgesia
Description: Standard post-operative analgesia orders will be followed.
Study NCT03518385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound,transvaginal scan
Description: The presence of fluid in the uterine cavity during hormonal stimulation.
Study NCT00732147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Description: 120 micrograms given subcutaneously before each meal X 3.
Study NCT00732147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 micrograms given subcutaneously before each meal x 3.
Study NCT03817385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: rTMS x 10 times
Study NCT03817385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic GT
Description: robotic gait training for 20 times
Study NCT03722550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides
Description: Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
Study NCT03722550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast-feeding
Description: Exclusive Breast-feeding up to 4 months of age
Study NCT03722550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk
Description: Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
Study NCT01371539 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
Study NCT02405130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary epinephrine
Description: after failure of standard therapy patients will treated with epinephrine
Study NCT02405130 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intracoronary epinephrine
Description: patients will receive standard therapy only
Study NCT00374881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study NCT00374881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine low dose
Study NCT00374881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol+Phenylephrine
Description: Sorbitol+Phenylephrine
Study NCT00374881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol+Phenylephrine+Morphine
Description: Sorbitol+Phenylephrine+Morphine
Study NCT00374881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol low concentration+Phenylephrine+Morphine
Description: Sorbitol low concentration+Phenylephrine+Morphine
Study NCT01338831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102
Study NCT00893750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET Truth Education
Description: Individual Narrative Exposure and Truth Education in Groups
Study NCT00893750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conflict Resolution and Social Competence Skills
Description: Conflict Resolution and Social Competence Skills in Groups
Study NCT00893750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Ways of Coping
Description: Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
Study NCT04135833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 60 mg